Lakewood-Amedex Biotherapeutics Inc.
corporate_fare Company Profile
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LABT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LABT spans 10-Q, 8-K, S-1, DEF 14A.
Recent high-impact activity:
- Q3 10-Q: Going Concern, $6.2M Nine-Month Loss, Cash Through January 2027
- Nasdaq Moves to Delist Lakewood-Amedex After Sub-$1 Bid; Hearing Request Is the Only Stay
- Lakewood-Amedex Pays $1.27M Cash to Retire All Series C Preferred
- Shareholders Approve 8x Authorized Share Increase and Reverse Split Authority
- First Patient Dosed in Phase 2a Trial of Nu-3 for Diabetic Foot Ulcers
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 152,917 shares in LABT as of the October 30, 2026 settlement, a 69.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 48.9% of LABT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for LABT, detected from its recent SEC filings · based on capital-structure filings through 2026-05-26.
Massive Dilution Confirmed · Ongoing Going Concern Warning
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →